Browse investments

Invest in Protagonist Therapeutics, Inc. on Stash

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs.

To buy fractional shares of Protagonist Therapeutics, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: PTGX

Protagonist Therapeutics, Inc.

$92.25

+8.98%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

PTGX Performance Breakdown

Share Price

$92.25

Today's change

0.95%

Year to date change (YTD)

136.66%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About PTGX

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs address two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company’s alpha-4-beta-7 (α4β7) antagonist PN-943 and its Interleukin-23 receptor (IL-23R) antagonist compound PN-235 are orally delivered investigational drugs that are designed to block biological pathways. PN-943 is an investigational, orally delivered, gut-restricted α4β7 specific integrin antagonist for inflammatory bowel disease (IBD). Its PN-235 is an orally delivered IL-23R specific antagonist for the treatment of IBD and non-IBD indications.

Protagonist Therapeutics, Inc. Stock Ticker

PTGX

For more information

https://www.protagonist-inc.com

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in Protagonist Therapeutics, Inc. on Stash

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs.

To buy fractional shares of Protagonist Therapeutics, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Protagonist Therapeutics, Inc. stock news

24/7 Wall Street

Oracle Plunges 12% Despite Earnings Beat as $50 Billion Spending Plan Stuns Investors

Yesterday we highlighted Oracle's massive $455 billion cloud backlog and the question of whether infrastructure spending would finally convert to sustainable margin expansion.

about 7 hours ago

CNBC

The Fed's hawkish cut, Oracle earnings, Coca-Cola's next CEO and more in Morning Squawk

The Federal Reserve cut interest rates by 25 basis points but struck a hawkish tone. Shares of Oracle dropped after the company missed Wall Street's revenue expectations.

about 8 hours ago

Business Insider

Warren Buffett hired Todd Combs to take over Berkshire's portfolio one day. Here's what close watchers say about his surprise exit.

Warren Buffett hired Todd Combs to eventually succeed him as Berkshire Hathaway's stock picker. Combs, one of Buffett's two investment managers and Geico's CEO, has quit to join JPMorgan.

about 10 hours ago

24/7 Wall Street

Fast-Casual Darling Grows Revenue 20% but Profit Margins Tell a Different Story

CAVA Group (NYSE: CAVA) and Chipotle Mexican Grill (NYSE: CMG) both reported Q3 2025 earnings in late October and early November.

about 8 hours ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy Protagonist Therapeutics, Inc. stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Protagonist Therapeutics, Inc.’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Protagonist Therapeutics, Inc.’s price can fluctuate throughout the course of each trading day—when you buy Protagonist Therapeutics, Inc. through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time Protagonist Therapeutics, Inc. stock price and the Protagonist Therapeutics, Inc. news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers two subscription plans: Stash Growth and Stash+.

Each plan can help you reach different goals and offers a unique combination of financial accounts and features. All plans include access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of Protagonist Therapeutics, Inc. stock is complete, you'll officially be a shareholder of Protagonist Therapeutics, Inc.!